NASDAQ:VOGX Vogenx Q2 2026 Earnings Report $34.13 +0.74 (+2.22%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Vogenx EPS ResultsActual EPS-$0.07Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AVogenx Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVogenx Announcement DetailsQuarterQ2 2026Date9/17/2026TimeAfter Market ClosesConference Call DateThursday, September 17, 2026Conference Call Time8:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Vogenx Earnings HeadlinesVogenx Inc's Quiet Period Set To End on September 21st (NASDAQ:VOGX)September 14 at 1:20 AM | americanbankingnews.comVogenx (VOGX) Stock Forecast & Price TargetSeptember 6, 2026 | investing.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 17 at 1:00 AM | Profits Run (Ad)WBB Securities initiates coverage of Vogenx (VOGX) with speculative buy ratingSeptember 4, 2026 | msn.comJones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public OfferingAugust 17, 2026 | prnewswire.comSee More Vogenx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vogenx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vogenx and other key companies, straight to your email. Email Address About VogenxVogenx (NASDAQ:VOGX), Inc. was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction. The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products. Vogenx was based in the United States and operated as a development-stage biopharmaceutical company. Detailed current information about its operations, product portfolio, geographic reach, and leadership is limited.View Vogenx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Aeluma’s Selloff Could Be Setting Up Its Next Big MoveCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageHoliday Shopping Is Almost Here—And Target May Be Ready to Win BigCan ServisFirst Keep Delivering?Banc of California Bets on Short-Term Pain3 Luxury Consumer Brands to Watch in a Beaten-Down Sector Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
